3 completed, 1 unknown. 3 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Unknown 1 |
| Not applicable | 1 | Completed 1 |
Follow Marcus Saemann: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Response Options to Blood Volume Monitoring in Fluid Overloaded Hemodialysis Patients UCR, UTR - Overhydration, Dry Weight Reduction | Not applicable | Completed | Marcus Saemann | 64 | 2011-09-01 | 2012-09-03 |
| Glucose Control in Pre-Diabetic Renal Transplant Patients Vildagliptin, Pioglitazone, Life-Style Modification - Impaired Glucose Tolerance, Kidney Transplantation | Phase 2 | Completed | Marcus Saemann | 51 | 2009-12-01 | 2011-12-05 |
| Treat-to-target Trial of Basal Insulin in Post-transplant Hyperglycemia Insulatard (long-acting insulin), Conventional - Hyperglycemia | Phase 2 | Completed | Marcus Saemann | 50 | 2009-01-01 | 2012-09-03 |
| Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients Certican (everolimus) + valganciclovir, Valganciclovir - Cytomegalovirus Disease | Phase 2 | Unknown | Marcus Saemann | 40 | 2008-12-01 | 2012-09-03 |
Cytomegalovirus Infections (1) · Glucose Intolerance (1) · Hyperglycemia (1) · Water Intoxication (1)
Congresses as Topic (1) · Everolimus (1) · Insulin, Long-Acting (1) · Isophane Insulin, Human (1) · Pioglitazone (1) · Valganciclovir (1) · Vildagliptin (1)
Austria (4)
Sabine Schmaldienst, MD (1) · Wilfred Druml, MD (1)